Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer
Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs MIAMI, July…
News
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others BASEL, Switzerland, LONDON, and NEW YORK,…
Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)
Science 37’s Metasite to Facilitate Phase 3 Study Enrollment by Expanding Access and Maximizing Convenience for…
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others BASEL, Switzerland, LONDON, and NEW YORK,…
Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)
Science 37’s Metasite to Facilitate Phase 3 Study Enrollment by Expanding Access and Maximizing Convenience for…
Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
NEW YORK, July 11, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that…
Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
NEW YORK, July 11, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that…
Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer
Proprietary T-Bolt™ technology dramatically broadens the benefits of immunotherapy by targeting the entire universe of cancer antigens …
Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer
Proprietary T-Bolt™ technology dramatically broadens the benefits of immunotherapy by targeting the entire universe of cancer antigens …
Velocity and Privia Health Enter Partnership to Embed Clinical Research Into Practice Sites
Dr. Paul Evans, Chief Executive and President of Velocity Dr. Paul Evans, Chief Executive and…
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
LAUSANNE, Switzerland, July 11, 2023 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced…
Velocity and Privia Health Enter Partnership to Embed Clinical Research Into Practice Sites
Dr. Paul Evans, Chief Executive and President of Velocity Dr. Paul Evans, Chief Executive and…
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
LAUSANNE, Switzerland, July 11, 2023 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced…
AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
StemPrintER outperformed the current market leader, OncotypeDX test, in stratifying patients according to their risk…
Psyence Appoints Intellectual Property Expert to Its Board of Directors
TORONTO, July 11, 2023 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF)…
AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
StemPrintER outperformed the current market leader, OncotypeDX test, in stratifying patients according to their risk…
Psyence Appoints Intellectual Property Expert to Its Board of Directors
TORONTO, July 11, 2023 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF)…
Iridia Announces Appointment of Buck Watia as Vice President, Corporate Development
Buck Watia to Lead Commercialization of Proprietary DNA Data Storage Technology that Promises to Transform…
Iridia Announces Appointment of Buck Watia as Vice President, Corporate Development
Buck Watia to Lead Commercialization of Proprietary DNA Data Storage Technology that Promises to Transform…
Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage…